Cargando…
Phase I trial of the novel taxane BMS-184476 administered in combination with carboplatin every 21 days
The aim of the study was to determine the maximum-tolerated dose and dose-limiting toxicities for BMS-184476, in combination with carboplatin, in patients with advanced solid tumours and to describe any preliminary antitumour activity associated with this regimen. Patients received combination thera...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2004
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409820/ https://www.ncbi.nlm.nih.gov/pubmed/15213727 http://dx.doi.org/10.1038/sj.bjc.6601885 |